Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BackgroundSimvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, anti-angiogenesis, and apoptosis. This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients.MethodsPatients received irinotecan 180 mg/m2 as a 90-min infusion followed by leucovorin 200 mg/m2 in a 2-h infusion, and then 5-FU 400 mg/m2 bolus injection followed by 2,400 mg/m2 as a 46-h continuous infusion. Treatment cycles were repeated every 2 weeks until documented disease progression, unacceptable toxicity, or patient’s refusal. Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest.ResultsFrom October 2005 to June 2006, 49 patients were enrolled. The overall response rate (ORR) was 46.9% (95% CI, 31.0–58.8) by intent-to-treat analysis and 45.8% (95% CI, 33.3–62.8) by per-protocol analysis. There were one complete response (CR) and 22 partial responses (PRs). Both CR and PRs were confirmed at least 4 weeks later. The disease-control rate was 83.7% (95% CI, 73.4–94.0). The median follow-up duration was 25.6 months (range, 20.9–28.8 months). The median survival of all patients was 21.8 months (95% CI, 14.4, 29.2). The median TTP was 9.9 months (95% CI, 6.4, 13.3). No patients experienced additional adverse effect that was definitely caused by simvastatin drug therapy in this trial.ConclusionThe combination of simvastatin plus FOLFIRI was a feasible regimen with promising antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“According to a Simon’s two-stage phase II optimal design [28], a sample size of 44 was required to accept the hypothesis that the true response rate is greater than 35% with 90% power, and to reject the hypothesis that the response rate is less than 15% with 5% signiWcance.”
MethodK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 2×
“Given the fact that TTP is often considered as clinical index reXective of anti-tumor activity of cytostatic drug, it was of particular interest to observe modestly prolonged TTP [9.9 months (95% CI, 6.4–13.3)] in simvastatin/FOLFIRI combination when compared with FOLFIRI alone in other studies (range 6.7–8.5 months)…”
ResultInfluentialTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 2×
“Given the fact that TTP is often considered as clinical index reXective of anti-tumor activity of cytostatic drug, it was of particular interest to observe modestly prolonged TTP [9.9 months (95% CI, 6.4–13.3)] in simvastatin/FOLFIRI combination when compared with FOLFIRI alone in other studies (range 6.7–8.5 months)…”
ResultInfluentialGlucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344 · cited 1×
“Of interest, simvastatin also undergoes lactonization via the glucuronidation pathway by UGT1A1 and 1A3 [24].”
Background
Cited by
Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer
Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.010 · Cited by 1,097
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Effect of statin therapy on colorectal cancer
Bardou, M., Barkun, A., & Martel, M. (2010) · Gut · doi:10.1136/gut.2009.190900 · Cited by 175
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr070 · Cited by 103
Self-citationTargeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis
Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02557-5 · Cited by 4
“Thirdly, through literature review, we found that there are additional mechanisms by which simvastatin enhances 5-FU [37–39].”
Metadata
- Authors
- Lee, J., Jung, K. H., Park, Y. S., Ahn, J. B., Shin, S. J., Im, S.-A., Oh, D. Y., Shin, D. B., Kim, T. W., Lee, N., Byun, J. H., Hong, Y. S., Park, J. O., Park, S. H., Lim, H. Y., & Kang, W. K.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2009-01-24
- Volume
- 64
- Issue
- 4
- Pages
- 657-663
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W1963581413
- Cited by
- 77
- References
- 5
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. https://app.cochat.ai/papers/10.1007/s00280-008-0913-5
- The paper
- Lee, J., Jung, K. H., Park, Y. S., Ahn, J. B., Shin, S. J., Im, S.-A., Oh, D. Y., Shin, D. B., Kim, T. W., Lee, N., Byun, J. H., Hong, Y. S., Park, J. O., Park, S. H., Lim, H. Y., & Kang, W. K. (2009). Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-008-0913-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.